Literature DB >> 19846967

Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.

Lazaros Skagias1, Ekaterini Politi, Andreas Karameris, Dimitrios Sambaziotis, Athanasios Archondakis, Apostolos Ntinis, Iraklis Moreas, Olympia Vasou, Helen Koutselini, Efstratios Patsouris.   

Abstract

BACKGROUND: Since its discovery in 1997, survivin has garnered significant interest due to its putative role as an inhibitor of apoptosis. Few studies have investigated the immunohistochemical status of survivin in urothelial bladder carcinoma. The subcellular localization of survivin (nuclear, cytoplasmic) and its differential predictive value is a parameter that previous studies have almost ignored. The aim of this study was to investigate the expression pattern of survivin in order to determine its potential prognostic significance.
MATERIALS AND METHODS: Archival tumor tissue from 80 patients with urothelial carcinoma were analysed by immunohistochemistry.
RESULTS: Nuclear and cytoplasmic positive scores of 61.25% (49/80) and 22.5% (18/80), respectively were found. Nuclear positive staining correlated strongly with increased grade (p=0.001), stage (p=0.039) and the probability of tumor recurrence (p=0.029). No relationship was found between the cytoplasmic survivin level and the clinicopathological parameters. Nuclear expression was identified as a significant independent predictor of relapse-free survival (p=0.016).
CONCLUSION: Nuclear expression of survivin reflects an adverse disease outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846967

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis.

Authors:  Shunzeng Lv; Ekaterina Turlova; Shigang Zhao; Huihui Kang; Mingzhi Han; Hong-Shuo Sun
Journal:  Tumour Biol       Date:  2013-10-08

2.  Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.

Authors:  Xiao-Yan Zou; Dong Ding; Na Zhan; Xiao-Ming Liu; Cheng Pan; Yu-Min Xia
Journal:  J Invest Dermatol       Date:  2014-09-03       Impact factor: 8.551

3.  Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.

Authors:  Hiroshi Kitamura; Toshihiko Torigoe; Yoshihiko Hirohashi; Hiroko Asanuma; Ryuta Inoue; Sachiyo Nishida; Toshiaki Tanaka; Naoya Masumori; Noriyuki Sato; Taiji Tsukamoto
Journal:  Virchows Arch       Date:  2012-11-20       Impact factor: 4.064

4.  Pro- and antiapoptotic markers in upper tract urothelial carcinoma associated with Balkan endemic nephropathy.

Authors:  Ljubinka Jankovic-Velickovic; Slavica Stojnev; Ana Ristic-Petrovic; Zana Dolicanin; Takanori Hattori; Kenichi Mukaisho; Mariola Stojanovic; Vladisav Stefanovic
Journal:  ScientificWorldJournal       Date:  2011-10-17

Review 5.  Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis.

Authors:  Chanhoo Jeon; Myong Kim; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

6.  Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer.

Authors:  Rafał Stec; Szczepan Cierniak; Arkadiusz Lubas; Urszula Brzóskowska; Tomasz Syryło; Henryk Zieliński; Aleksandra Semeniuk-Wojtaś
Journal:  Pathol Oncol Res       Date:  2019-06-19       Impact factor: 3.201

Review 7.  Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans.

Authors:  Maria Malvina Tsamouri; Thomas M Steele; Maria Mudryj; Michael S Kent; Paramita M Ghosh
Journal:  Biomedicines       Date:  2021-10-14

Review 8.  Natural products: a hope for glioblastoma patients.

Authors:  Raghupathy Vengoji; Muzafar A Macha; Surinder K Batra; Nicole A Shonka
Journal:  Oncotarget       Date:  2018-04-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.